NEUVIOR · DISTRIBUTED PRESENCE
Glasgow. London. Mumbai.
Three cities connect NEUVIOR’s Scottish origin, commercial activity led by the founder and pharmaceutical network in India.
Different functions.One company direction.
THREE DISTINCT FUNCTIONS
Origin. Company building. International reach.
Glasgow anchors the company record and Scottish innovation work. London concentrates commercial and institutional activity led by the founder. Mumbai extends market and pharmaceutical relationships. Glasgow is the registered office; London and Mumbai describe active work, not separately incorporated entities or regulated facilities.
55.8642° N · 4.2518° W
Glasgow
Origin and registered Scottish baseNEUVIOR was established in Scotland and maintains its registered office in central Glasgow. The city anchors the company’s corporate origin and connection to the Scottish innovation ecosystem.
Glasgow is the administrative anchor for company records and defined innovation work, linking NEUVIOR to Scotland’s life sciences, technology and advanced manufacturing networks.
51.5072° N · 0.1276° W
London
Commercial and institutional activity led by the founderLondon supports company building led by the founder, commercial conversations and engagement across the UK’s healthcare, pharmaceutical, investment and media networks.
That proximity supports faster conversations with institutional decision makers, collaborators, investors and publishers shaping the company’s next stage.
19.0760° N · 72.8777° E
Mumbai
India market and pharmaceutical network engagementMumbai connects NEUVIOR with market development in India, strategic relationships and a pharmaceutical ecosystem spanning medicines, supply, formulation and technology.
It gives the founder a direct bridge into one of the world’s most consequential pharmaceutical markets. It also supports the relationships needed to understand opportunity between the UK and India.
- Podcast appearance. AI Ethics Now / University of Warwick IATL. AI and Accountability: When Does a Suggestion Become a Decision?. 23 August 2026.
- Contributed analysis. Pharmaphorum. Approval is not access: Pilots' real test is implementation. 18 August 2026.
- Contributed opinion. TechRadar Pro. Five questions to test whether an AI stack is truly under your control. 11 August 2026.
- Founder commentary. ET Pharma. India’s pharma quality reset will be won after the inspector leaves. 4 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. From invention to adoption: the work between. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. A trade deal is not a patient pathway. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Insights. NHS digital programmes do not fail on dashboards. They fail on deployment. 20 March 2026.
- Founder viewpoint. Pharmaceutical Technology. Why the India UK trade deal now needs a five gate implementation ledger. 28 July 2026.
- Release derived reporting. TheBusinessDesk.com. NEUVIOR company support coverage. 19 May 2026.
- Founder commentary. Startups Magazine. What my dad's corner shop taught me. 6 May 2026.
- Expert commentary. Manufacturing Chemist. NICE approval is not enough: why the UK's next medicines challenge is operational delivery. 4 June 2026.
- Founder commentary. PharmaTimes. How we roll. 10 June 2026.
- Founder commentary. BusinessCloud. Why neurodivergent founders can excel at building complex systems. 18 March 2026.
- Partner announcement. Biorenewables Development Centre. NEUVIOR research record. 20 April 2026.
Classified public record
THREE CITIES · ONE PUBLIC RECORD
Follow the thinking and public record across NEUVIOR’s three city model.
Read the Scottish company record, founder led UK commentary and the UK India implementation argument. These records do not establish separate offices, facilities or regulated operations.
NEUVIOR company support coverage
Scottish regional business coverage recording publicly reported SMART:SCOTLAND support for NEUVIOR.
See the Scottish company recordA trade deal is not a patient pathway
A trade agreement can change the commercial and policy context. The value depends on whether each implementation gate has evidence, ownership and a route to learning.
See the proposed UK India implementation pathThe 30p rule: how discipline builds trust
The smallest amount can reveal whether a business understands its margins, respects its records and keeps the promises hidden inside the numbers.
Understand the Glasgow founder origin
NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.
ONE OPERATING MODEL
Three networks. One company direction.
This model gives NEUVIOR proximity to Scotland’s innovation base, London’s institutional network and one of the world’s most important pharmaceutical markets. The value is in the connection between them. Each city supports a different kind of operation.
